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Abstract
Familial amyloidotic polyneuropathy (FAP) is a systemic conformational disease characterized by extracellular amyloid fibril
formation from plasma transthyretin (TTR). This is a crippling, fatal disease for which liver transplantation is the only
effective therapy. More than 80 TTR point mutations are associated with amyloidotic diseases and the most widely accepted
disease model relates TTR tetramer instability with TTR point mutations. However, this model fails to explain two
observations. First, native TTR also forms amyloid in systemic senile amyloidosis, a geriatric disease. Second, age at disease
onset varies by decades for patients bearing the same mutation and some mutation carrier individuals are asymptomatic
throughout their lives. Hence, mutations only accelerate the process and non-genetic factors must play a key role in the
molecular mechanisms of disease. One of these factors is protein glycation, previously associated with conformational
diseases like Alzheimer’s and Parkinson’s. The glycation hypothesis in FAP is supported by our previous discovery of
methylglyoxal-derived glycation of amyloid fibrils in FAP patients. Here we show that plasma proteins are differentially
glycated by methylglyoxal in FAP patients and that fibrinogen is the main glycation target. Moreover, we also found that
fibrinogen interacts with TTR in plasma. Fibrinogen has chaperone activity which is compromised upon glycation by
methylglyoxal. Hence, we propose that methylglyoxal glycation hampers the chaperone activity of fibrinogen, rendering
TTR more prone to aggregation, amyloid formation and ultimately, disease.
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Introduction
Familial amyloidotic polyneuropathy (FAP) is an autosomic
dominant neurodegenerative disease characterized by the forma-
tion of amyloid fibril deposits, mainly composed of transthyretin
(TTR), in different organs and tissues [1,2]. It is a progressive and
crippling disease that ultimately leads to death. FAP is associated
with point mutations in TTR, a homotetrameric protein mainly
produced in the liver and found in the plasma, cerebrospinal fluid
and saliva. Over 80 TTR point mutations are related to TTR
amyloidogenic behavior and amyloidotic diseases leading to
systemic amyloid fibril formation with the characteristic b-sheet
cross structure commonly found in several other neurodegenera-
tive disorders such as Alzheimer and Parkinson [3]. Since TTR is
mainly produced by the liver, the only effective therapeutic option
for FAP is the orthotopic liver transplantation (OLT) from
cadaveric donors. This method was first validated in 1990 in
Sweden since OLT leads to the clearance of V30M TTR from the
plasma of the FAP transplanted recipient [4]. To obviate the
shortage of livers available for transplantation, domino liver
transplantation (DLT) was recently introduced in which a liver
from a FAP patient is transplanted to a patient with liver failure.
DLT introduces mutated TTR variants in circulation, increasing
the risk of FAP development [5]. Currently, the main hypothesis
for FAP pathogenesis considers that point mutations cause TTR
tetramer instability favoring its dissociation to non-native mono-
meric species with the ability to self-associate [6]. These soluble
monomers tends to aggregate and evolve to insoluble multimeric
forms leading to amyloid fibrils with the characteristic b-sheet
cross structure [6]. However, this model fails to explain two crucial
aspects of TTR amyloid formation and pathogenesis. First,
mutations are not required for TTR amyloid formation. Indeed,
non-mutated TTR also forms amyloid deposits in systemic senile
amyloidosis, a crippling disease in later life [7]. Also, wild type
TTR continues to accumulate into amyloid deposits even after
liver transplantation [8]. In fact, after liver transplantation, FAP
patients present a shorter life-span than expected which may be
associated with progression of neuropathy due to continued
deposition of non-mutated TTR in amyloid form [8]. Moreover, a
considerable number of TTR mutation carriers are asymptomatic
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intrinsic amyloidogenic nature of TTR and are not absolute
predictors of amyloid formation or disease development. Second,
time of disease onset varies by decades for different patients
bearing the same mutation [10] and also the genetic trait
frequency in different areas is not correlated with the number of
known cases [11]. Furthermore, discordant symptoms in homo-
zygote twins were observed: while one of the twins underwent liver
transplantation, the other remained healthy for at least 8 years
after his brother’s disease onset [12]. It is also noteworthy that the
homozygous carriers of the amyloidogenic TTR variant V30M do
not develop a more aggressive disease form than heterozygous
ones [13,14,15]. The most likely explanation for these observations
is the involvement of non-genetic factors in FAP onset and disease
progression. Uncovering the nature of these non-genetic factors
and the molecular mechanisms of their actions is likely to have a
major impact on our knowledge of the molecular mechanisms of
other conformational diseases. The two most important non-
genetic factors that may directly affect protein structure and
function are protein-protein interactions and post-translational
modifications. In the first one, it is remarkable that TTR does not
form amyloid deposits in the cerebrospinal fluid. TTR interacts in
the cerebrospinal fluid with different interactors than in the
plasma, like thyroxine T4, which prevents TTR amyloid fibril
formation [16]. Concerning the second, among a legion of known
post-translational modifications, glycation is the common link in
amyloidotic pathologies, being found in Alzheimer, Parkinson and
also in FAP [17]. One of the most powerful glycation agents in vivo
is methylglyoxal formed in all living cells from dihydroxyacetone
phosphate and D-glyceraldehyde 3-phosphate, as a non-enzymatic
glycolysis by-product [18]. Methylglyoxal irreversibly modifies
both lysine and arginine residues in proteins forming advanced
glycation end products, termed MAGE (methylglyoxal-derived
advanced glycation end products) [18]. Arginine-derived MAGE
appear to be more relevant considering the existence of specific
receptors for hydroimidazolones [19]. Argpyrimidine [Nd-(5-
hydroxy-4,6-dimethylpyrimidin- 2-yl)-L-ornithine] is another ar-
ginine MAGE [20] abundantly found in vivo [21,22]. Methylgly-
oxal glycation was found in several conformational pathologies
such as Alzheimer [23,24,25,26], dialysis-related amyloidosis [27]
Parkinson [28], prion diseases [29], hemodialysis-related A_2M
amyloidosis, [30], murine ApoAII amyloidosis [31]. We previously
reported that amyloid fibrils extracted from FAP patients are
glycated by methylglyoxal, bringing further support to the
hypothesis that methylglyoxal-derived protein glycation is involved
in conformational diseases [22].
In the present study, we found that FAP patients present higher
levels of argpyrimidine-modified proteins in human plasma.
Moreover, we discovered that fibrinogen is a specific glycation
target with an increased glycation in FAP patients and is one of the
main TTR interacting proteins in plasma. Upon glycation by
methylglyoxal, we observed a significant reduction of the fibrinogen
chaperone activity in vitro. Considering that we observed that
fibrinogen prevents plasma TTR thermal-induced protein aggrega-
tion, we created a new molecular model for TTR amyloidogenesis in
vivo. Briefly, in FAP, increased glycation of fibrinogen reduces its
chaperone activity, reducing TTR tetramer stability and triggering
the pathway to aggregation, amyloid formation and disease.
Materials and Methods
Ethics Statement
The ethics board of the Hospital de Curry Cabral approved all
procedures regarding human blood collection. All subjects involved
gave informed written consent and the protocol was approved
according to EEC ethic rules and the Declaration of Helsinki.
Human plasma Collection
Blood samples from control individuals, FAP patients (four
females each group, age range 26–33 years) and transplanted
individuals (males age range 24–41 years for OLT (orthotopic liver
transplantation) and age range 43–58 years for DLT (domino liver
transplantation) were collected to citrate containing tubes,
centrifuged at 1,800 g for 5 min at 4uC and the collected plasma
was immediately frozen at 280uC until further analysis. Blood was
collected by venous puncture to citrate containing tubes.
Poliacrylamide Gel Electrophoresis
Plasma proteins were separated by sodium dodecyl sulfate
polyacrilamide gel electrophoresis (12% SDS-PAGE), in mini-gel
format (767 cm Tetra system from Bio-Rad). Twenty micrograms
of plasma protein were used per lane. Protein concentration was
determined by the Bradford protein assay, using bovine serum
albumin as standard. Samples were diluted 10 fold in MilliQ water
and mixed with reduction buffer (62.5 mM Tris-HCl, pH 6.8,
20% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) b-mercaptoetanol).
Prior to electrophoresis, samples were heated at 100uC for 5 min.
Protein bands were stained with Coomassie Brilliant Blue R-250.
Two Dimensional Electrophoresis
Samples containing 15 or 250 mg of plasma protein were used
for IEF (isoelectric focusing) using immobiline dry strips of 7 or
13 cm, respectively, with a non linear pH gradient from 3 to 11
[32] (Amersham Biosciences). After IEF separation, proteins were
reduced and alkylated in the dry strip. Second dimension SDS-
PAGE was performed using 12% SDS-PAGE. Protein spots were
stained with Coomassie Brilliant Blue R-250.
Western Blotting
For Western blot analysis, proteins were transferred to PVDF
membranes (Millipore) and stained with Ponceau S to monitor
protein transfer. Membranes were blocked overnight at 4uC with
TBS-T (10 mM Tris–HCl, 150 mM NaCl, pH 7.5 with 0.1%
Tween 20) containing 5% (w/v) skimmed milk. Thereafter, the
membranes were incubated overnight at 4uC with the primary
antibody used in TBS-T containing 1% (w/v) skimmed milk.
Antibodies used were: anti-human TTR polyclonal antibody
(Santa Cruz Biotechnology) at a dilution of 1:5000; anti-
argpyrimidine (Jaica) at a dilution of 1:2000; anti-human soluble
RAGE (Santa Cruz Biotechnology) at a dilution of 1:5000; anti-
fibrinogen (Calbiochem) at a dilution of 1:10000. Membranes
were washed three times for 10 min each with TBS and incubated
for 1 h at room temperature with anti-rabbit IgG (Roche) (at
1:10000 dilution) or anti-mouse IgG (Roche) (at 1:10000 dilution).
Immunoreactivity was detected with diaminobenzidine as a
chromomeric substrate, following the manufacturer’s instructions
(Pierce). Each dried blot was scanned at 600 dpi, saved as a TIFF
file and analysed using the ‘‘Gel Analysis’’ functions of ImageJ
program (National Institutes of Health, available at http://rsb.
info.nih.gov/ij/). Background correction was done using a ‘‘rolling
ball’’ method with a radius of 4 times the width of a band. Result
of the analysis is a value for each band which is proportional to the
Integrated Density Value (IDV) of that band [33].
In Gel Protein Digestion
Protein bands were manually excised from the gels and digested
using trypsin as described [33,34,35]. Briefly gel protein bands
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acetonitrile and subsequently with 100% acetonitrile. Cysteine
residues were reduced with 10 mM DTT and alkylated with
50 mM iodoacetamide. Gel pieces were dried by centrifugation
under vacuum and rehydrated in digestion buffer containing
50 mM NH4HCO3 and 6.7 ng.mL
21 of trypsin (modified porcine
trypsin, proteomics grade, Promega) at 4uC. After 30 min, the
supernatant was removed and discarded and 20 mLo f5 0m M
NH4HCO3 were added. Digestions were allowed to proceed at
37uC overnight (16–18 hours). After digestion, the remaining
supernatant was removed and stored at 220uC.
Mass Spectrometry
For protein identification and glycation assignment, a MALDI-
TOF/TOF 4800 Plus mass spectrometer (Applied Biosystems) was
used. Desalting and concentration of tryptic peptides was carried
out with in-house made chromatographic microcolumns using
GELoader tips packed with POROS R2 (Applied Biosystems).
Peptides were directly eluted from the microcolumns onto the
MALDI plate using a-ciano-4-hydroxycinnamic acid (5 mg.ml
21)
in 50% (v/v) acetonitrile with 0.1% (v/v) formic acid as matrix.
MS Experiments were performed in positive reflectron mode for
monoisotopic peptide mass determination. The mass spectrometer
was externally calibrated using des-Arg-Bradykinin (904.468 Da),
angiotensin 1 (1296.685 Da), Glu-Fibrinopeptide B (1570.677 Da),
ACTH (1–17) (2093.087 Da), and ACTH (18–39) (2465.199)
(4700 Calibration Mix, Applied Biosystems). MS Spectra were
collected in a result-independent acquisition mode, typically using
1000 laser shots per spectra and a fixed laser intensity of 3000 V.
For tandem experiments, fifteen of the most intense precursors
were selected for MS/MS, the weakest precursors being
fragmented first. MS/MS Analyses were performed using CID
(Collision Induced Dissociation) with 1 kV collision energy and
1610
6 torr air pressure. 2000 Laser shots were collected for each
MS/MS spectrum using a fixed laser intensity of 4000 V. Raw
data were generated by the 4000 Series Explorer Software v3.0
RC1 (Applied Biosystems) and tryptic peptide contaminant m/z
peaks resulting from trypsin auto digestion (842.508 Da; 1045.564
Da; 2211.108 Da; 2225.119 Da) were excluded when generating
the peptide mass list used for comparison with the theoretical
tryptic digest. Proteins were identified using the GPS explorer
software (Applied Biosystem) and identifications were further
confirmed using the ProteinPilot software (Applied Biosystem), as
previously reported [36]. To identify glycated-modified peptides
and amino acid residues, an inclusion list with predicted
monoisotopic masses for modified peptides of the identified
proteins were loaded in the tandem MS mode. Confirmation of
the presence of glycated peptides by mass spectrometry was
performed as previously described [37,38]. Briefly, as protein
glycation modifies lysine and arginine side chains it causes
misscleaves when hydrolysing proteins with trypsin. If a lysine or
an arginine residue is modified, it is possible to predict the mass
increase associated to any given known MAGE in a peptide with a
misscleavage. The relative quantitation of TTR variants in
heterozygotic subjects by mass spectrometry was performed as
previously described [39,40], briefly tryptic peptides were desalted
and concentrated using Poros reverse phase R2 (Applied
Biosystems) and eluted directly to the MALDI target AnchorChip
(Bruker Daltonics, Bremen) with a matrix solution of a-cyano-4-
hydroxycinnamic acid (Fluka) prepared at a concentration of
10 mg.mL
21 in 50% (v/v) acetonitrile with 0.1% (v/v) trifluroacetic
acid. Peptide mixtures were analyzed by MALDI-FTICR-MS in a
Bruker Apex Ultra, Apollo II Combi-Source (Bruker Daltonics),
with a 7 Tesla magnet (Magnex Corporation). Monoisotopic
peptide masses were determined using the SNAP 2 algorithm in
Data Analysis software version 4.0 (Bruker Daltonics). External
calibration was performed by using bovine serum albumin tryptic
digest spectrum and the data processed and analyzed with Biotools
3.2 (Bruker Daltonics).
TTR-GST Pull Down assay in plasma
Human TTR cloned inp426GPD plasmid(akind gift fromTiago
Outeiro, Instituto de Medicina Molecular da Universidade de
Lisboa, Portugal) was cleaved with the restriction enzymes BamHI
and XhoI. The inserts were purified after electrophoresis separation
on 1% (w/v) agarose gel in TBE buffer. The expression vector
pGEX 4T.2-TTR was obtained by ligation of the inserts with the
expression vector pGEX 4T.2 (Amersham biosciences), which was
doublydigestedwithBamHIandXhoI.ThevectorpGEX4T.2-TTR
was transformed into E. coli DH5a and purified using the High Pure
Plasmid Isolation Kit (Roche). For the recombinant protein
expression and purification, the resulting construct was transformed
into E. coli BL21
+ by heat shock and a single colony was used to
inoculate 10 mL of Luria Broth medium supplemented with
ampicillin (50 mg.mL
21)a t3 7 uC with shaking. The culture was
grown overnight and 10 mL were used to inoculate 1 L of LB
medium at 37uC. Protein expression was induced with 1 mM IPTG
(isopropyl-b-D-thiogalactopyranoside) when the absorbance at
600 nmreached0.4.After3 hoursofgrowth,cellswereimmediately
chilled on ice and harvested by centrifugation at 15000 g for 20 min
at4uC.Cells were frozenovernight at280uCand afterwardsthecell
pellet was suspended in 10 mL phosphate-buffered saline (PBS),
pH 7.4, sonicated 10 times for 30 s and centrifuged for 20 min at
14000 g at 4uC. The supernatant was stored at 280uCu n t i lu s e .
TTR in fusion with glutathione S-transferase (GST) (pGEX 4T.2-
TTR) and GST alone (pGEX 4T.2) were purified with gluthatione
sepharose 4BT beads (Amersham). For the pull-down assay, the
recombinant proteins and plasma (diluted 1:2 in incubation buffer,
100 mM potassium acetate, 30 mM Hepes-KOH, pH 7.5, supple-
mented with 4 mM of leupeptine, aprotinine and PMSF protease
inhibitors) were incubated with rotation at 4uC for 3 hours and
washed four times with washing buffer (100 mM potassium acetate,
30 mM Hepes-KOH at pH 7.5, 2 mM of leupeptine, aprotinine
and PMSF). Plasma was diluted 1:2 in washing buffer before
incubation. After washing, bound proteins were eluted from the
beads with denaturating buffer (62.5 mM Tris-HCl, pH 6.8, 20%
(v/v) glycerol, 2% (w/v) SDS, 5% (v/v) b-mercaptoetanol) and
boiled for 5 min. Eluted proteins were separated by SDS-PAGE
using 12% resolving gels, which were silver stained using a silver
staining kit (GE Healthcare). Each pull down assay was repeated at
least three times.
Methylglyoxal preparation
High purity methylglyoxal was prepared by fractional distilla-
tion under reduced pressure in nitrogen atmosphere as described
[41]. Once prepared, methylglyoxal solutions were standardized
by enzymatic assay with glyoxalase I and II. Purity was verified by
HPLC analysis and
13C NMR (Bruker advance 400 MHz).
Glycation in vitro of a-crystallin and human fibrinogen by
methylglyoxal
Bovine lens a-crystallin (Sigma) and human whole fibrinogen
(Calbiochem) (10 mg.ml
21) in 0.1 M sodium phosphate buffer
(pH 7.4) were incubated with 2.5 and 10 mM of methylglyoxal in
sterile conditions for 7 days at 37uC. Following incubations, all
samples were dialyzed against 0.1 M sodium phosphate buffer
(pH 7.4) for 48 hours at 4uC.
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fibrinogen
Chaperone activity of a-crystallin and human fibrinogen were
assayed in a Beckman DU 7400 spectrophotometer. Total
reaction volume was 2.5 ml. Five milligrams of insulin or two
milligrams of lysozyme (Sigma) were incubated with 2 mM DTT
in 0.1 phosphate buffer (pH 7.0) containing 2 mM EDTA at
37uC. Protein aggregation was followed by the absorption increase
due to increased light scattering in time, monitored at 360 nm for
60 min at 37uC. DTT is a commonly used aggregation induction
chemical agent. By reducing sulfhydryl bonds, proteins adopt a
linear conformation and become prone to aggregation, most likely
due to exposure of hydrophobic regions and the onset of
nucleation centres [42]. To assay chaperone activity, glycated
and non-glycated a-crystallin and human fibrinogen were added
to the mixture at twice the molar concentration of the target
protein.
Results
Decreased TTR stability in FAP patients
TTR is a tetramer composed of two dimers that bind to each
other and due to the large difference in the number of hydrophilic
interactions, the monomer-monomer contacts within the dimer
are more stable than the dimer-dimer interactions [43]. TTR
tetramer and dimer dissociation are essential steps towards
aggregation and amyloid fibril formation. Therefore, we analysed
the relative amounts of TTR monomers and dimers in FAP and
control subjects by SDS-PAGE, as previously used to evaluate the
relative amount of TTR dimer to monomer species [44]. Also, the
stable sample-specific dimer/monomer ratios, achieved under
conditions of partial dimer to monomer transition, reflect the
conformational monomer stability relative to the dimeric form
[45]. Once a dimer dissociates, the monomers are captured in a
complex with SDS and their ability to associate as a dimer is
compromised. After SDS-PAGE separation, under conditions of
partial dimer to monomer transition, TTR from control and FAP
groups was detected by Western blot, allowing the observation of
both dimer and monomer and also to perform a relative
quantification (Figure 1A). Monomer and dimer area signals were
quantified using ImageJ software. The signal intensity of each
protein band was normalized using the sRAGE protein band
signal (Figure 1C), for each lane, as loading control. We observed
that FAP individuals present a significantly lower ratio of dimer/
monomer than control individuals (Figure 1D, t-test for the
significance of the difference between the means of two
independent samples; p=0.0253). This observation is in agree-
ment with in vitro models of FAP amyloidosis, which revealed a
positive relationship between TTR amyloidogenic potential due to
a mutation and tetramer stability decrease [6].
Differential plasma protein glycation in FAP patients
We previously discovered that argpyrimidine is present in
amyloid fibrils from Portuguese type FAP patients [22], being the
first evidence that methylglyoxal-protein glycation is involved in
FAP and that glycation might play an important role in this
pathology. In this work, we compared the glycated plasma
proteomes from control subjects and FAP patients, targeting
argpyrimidine as a specific marker of methylglyoxal-derived
glycation. Plasma proteins from control and FAP individuals were
separated by SDS-PAGE and argpyrimidine-modified proteins
were detected by Western blot with a specific antibody against this
MAGE (Figure 1B). Although glycated proteins were found in
control and FAP subjects, in the latter case, a higher level of
argpyrimidine modified proteins are present in comparison to
control subjects. This is particularly noticeable in a protein band
with a molecular mass of 80 kDa which shows a strong signal for
argpyrimidine only in FAP individuals and corresponds to a faint
protein band in control subjects (Figure 1B). It is noteworthy that
glycated proteins present a similar pattern in all four controls and
FAP individuals, showing a high homogeneity and specificity of
plasma protein glycation even in different individuals.
To identify these argpyrimidine modified proteins, plasma
proteins were separated by 2D-PAGE and glycated proteins were
detected by Western blot as before (Figure 2A). In red (spots 1–11)
we assigned glycated proteins found in both control and FAP
individuals, whereas blue (spots 12–16) shows assigned glycated
proteins found exclusively in FAP patients. The molecular mass of
these proteins spots is similar to the protein bands detected by
Western blot for argpyrimidine in one-dimensional electrophoresis
and most likely corresponds to multiple forms of the same protein.
All assigned protein spots were excised from Coomassie stained
two dimensional gels (Figure 2B), trypsin digested and proteins
identified by MALDI-TOF-TOF-MS using tandem MS data. All
identified proteins are reported in Table 1. The differentially
argpyrimidine glycated proteins in FAP individuals were unequiv-
ocally identified as several isoforms of fibrinogen and immuno-
globulins. The glycation of these identified proteins was further
Figure 1. Western blot analysis of human plasma proteins.
Samples from four control and four FAP individuals were analysed to
detect (A) TTR; (B) Argpyrimidine-modified proteins and (C) soluble
RAGE; (D) Ratio between the intensity of TTR dimer and monomer. The
two-tailed P value equals 0.0253. This difference is statistically
significant with a 95% confidence interval.
doi:10.1371/journal.pone.0024850.g001
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group, MS spectra of tryptic digested glycated proteins contains
information regarding the nature and location of the glycated
amino acid residue [38]. Since only arginine residues are modified
by methylglyoxal with the formation of argpyrimidine, tryptic
digestion of glycated proteins produces peptides with an arginine
misscleavage associated with an 80 Da mass increase, character-
istic of an argpyrimidine modification. To identify the glycated
peptides, protein spots corresponding to the differentially glycated
proteins were removed from the 2D-PAGE gels of FAP patients
plasma, digested with trypsin and analysed by MS. Proteins from
control individuals 2D gels spots, matching the glycated proteins
spots in the FAP individuals 2D gels, were also removed and the
tryptic digested protein mass spectra were acquired and compared.
A peptide was considered to be glycated only if it was absent from
the MS spectra of the control sample. From this analysis, it was
possible to observe several glycated peptides of the identified
proteins, absence from the corresponding protein spot removed
from control individuals, thus confirming, at a molecular level,
that glycation occurred and argpyrimidine was present.
Figure 2. Two dimensional electrophoresis of control and FAP plasma proteins stained with Coomasie and Western blot analysis of
argpyrmidine modified proteins. (A) Full gel image; (B) Zoom image of the gel area at which protein spots were removed. Assigned protein spots
were excised for protein identifications (Table 1). Red marks correspond to common glycated proteins and blue marks correspond to protein glycated
differentially in FAP individuals.
doi:10.1371/journal.pone.0024850.g002
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FAP patients were related to any diabetes risk factors, we analysed
the soluble forms of the RAGE protein (sRAGE) by Western blot.
An association between the circulating sRAGE levels and diabetes
was previously observed [46] and this condition that lead to an
accumulation of glycation adducts. In our case, no differences
were observed in sRAGE levels between the control and FAP
patients, in agreement with the lack of diabetes background in
FAP individuals.
Plasma protein glycation increases and TTR stability
decreases over time in DLT individuals
Since plasma TTR is produced by the liver, disease progression
can be halted by OLT from cadaveric donors, leading to the
clearance of mutated TTR from the plasma of a FAP transplanted
recipient [47]. As the livers from FAP patients undergoing OLT are
functionally normal, except for the production of a mutated TTR
variant,thedominolivertransplantation(DLT),inwhich FAPlivers
are transplanted to patients with liver failure, was recently
introduced. Thus, DLT replaces non-mutated TTR by the
amyloidogenic TTR variant V30M. As the age of disease onset in
FAP TTRV30M ranges from the late 20s to the early 40s, it was
expected that livers explanted from FAP patients would function in
recipients without formation of amyloid fibrils for a long period of
time. However, at least two recent reports indicate that amyloid
deposition or FAP symptoms appeared in domino recipients much
sooner than expected [48,49]. To investigate a possible role of
protein glycation in this rapid disease progression, we monitored
TTR dimer/monomer ratios and the glycation levels of samples
from individuals that were subjected to OLT and DLT, from 1
month to 11 years (OLT) and from 2 months to 4 years (DLT) after
liver transplantation. As shown in Figure 3A, TTR dimer maintains
its stability over time in FAP individuals that were subjected to
OLT, for that moment on having only non-mutated TTR in
circulation. Likewise, there is no change over time both in the
number and relative amount of glycated plasma proteins after liver
transplantation (Figure 3A). The opposite was observed in
individuals subjected to DLT. As shown in Figure 3B, the glycation
of plasma proteins increases over time after DLT. In addition, for
the same time lapse we observed a marked reduction of TTR dimer
stability in these individuals. Thus, a relationship between a
reduction of the TTR dimer stability and an increase in the
glycation levels is apparent in patients subjected to DLT. In this
work, all TTR mutation carrying individuals or patients subjected
to DLT are heterozygous, meaning that the liver expresses both the
mutated (V30M) and the native TTR form. To exclude the
hypothesis that the reduced TTR dimer stability could be due to the
different amounts of the two TTR forms (native and V30M)
expressed over time, we determined the WT to V30M ratio by
MALDI–FTICR-MS, as previously described by us [39,40]. No
significant differences were observed between the ratios of the two
TTR forms. As expected, this ratio only shows slight differences
between different individuals (Table S1, Figure S1).
Fibrinogen is a TTR protein interaction partner in plasma
To uncover the transthyretin protein interaction network in
plasma, TTR affinity purification assays were used to identify its
putative protein binding partners. For these assays, TTR was
expressed in bacteria as a GST fusion product, purified and used
as bait for pull down assays from control and FAP plasma. As
negative control, GST was expressed in bacteria, purified and used
as bait. The proteins specifically eluting with the TTR tagged
protein were identified by MS/MS peptide mapping using
MALDI TOF-TOF MS. As depicted in Figure 4A, nine proteins
Table 1. Identification of argpyrimidine-modified proteins in human plasma.
Spot Identification Accession code
Protein
Score
Protein
Score C. I. %
Total Ion
Score
Total Ion
C. I. %
Peptides
Matched
1 Fibrinogen beta chain FIBB_HUMAN 619 100 469 100 19
2 Fibrinogen beta chain FIBB_HUMAN 628 100 467 100 20
3 Fibrinogen beta chain FIBB_HUMAN 899 100 711 100 22
4 Fibrinogen beta chain FIBB_HUMAN 892 100 676 100 22
5 Fibrinogen beta chain FIBB_HUMAN 642 100 449 100 20
6 Ig gamma-1 chain C region IGHG1_HUMAN 595 100 528 100 17
Ig gamma-3 chain C region IGHG3_HUMAN 218 100 189 100 7
7 Ig gamma-1 chain C region IGHG1_HUMAN 468 100 380 100 13
8 Ig gamma-1 chain C region IGHG1_HUMAN 606 100 539 100 16
Ig gamma-1 chain C region IGHG1_HUMAN 576 100 477 100 16
9 Ig gamma-1 chain C region IGHG1_HUMAN 586 100 481 100 16
Ig heavy chain V-III region TIL HV304_HUMAN 109 100 83 100 6
10 Ig gamma-1 chain C region IGHG1_HUMAN 612 100 511 100 13
11 Ig gamma-1 chain C region IGHG1_HUMAN 610 100 514 100 11
12 Fibrinogen beta chain FIBB_HUMAN 790 100 586 100 12
13 Fibrinogen beta chain FIBB_HUMAN 644 100 507 100 9
14 Fibrinogen alpha chain FIBA_HUMAN 309 100 168 100 7
15 Ig alpha-1 chain C region IGHA1_HUMAN 402 100 358 100 8
16 Ig alpha-2 chain C region IGHA2_HUMAN 221 100 191 100 5
Spot numbers correspond to the ones assigned in Figure 2B.
doi:10.1371/journal.pone.0024850.t001
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five were co-purified with TTR from both control and FAP
plasma (proteins bands 1, 2, 3, 4 and 8, labelled with red arrows),
three were co-purified only from FAP plasma (protein bands 5, 6
and 7, labelled with green arrows) and one was purified only from
control plasma (protein band 9, labelled with blue arrow). The
retinol binding protein (RBP) was identified in co-elutions from
both control subjects and FAP patients, validating the pull down
experiment since RBP is a well characterized TTR binding
partner in plasma and the cephalorachidian fluid (Figure 4A,
protein band 8). Several proteins were identified as TTR
interacting partners in plasma, namely albumin, immunoglobulins
and cis-trans isomerase (Table 2). Among these, fibrinogen
deserves a closer look not only because of its recently discovered
chaperone activity [50] but also due to its differential glycation
pattern that distinguishes control subjects from FAP patients. To
further validate this result, the affinity purification assay was
repeated and fibrinogen beta chain was detected by Western blot
(Figure 4B). Fibrinogen was unequivocally purified by TTR tagged
protein pull-down assay from both control and FAP patients.
Considering the fact that protein glycation by methylglyoxal is
known to exert effects on the activity of chaperone proteins we
speculated that this could also be the case of fibrinogen and as such
to be related with TTR stability and the molecular disease
mechanisms of FAP.
Fibrinogen prevents plasma TTR thermal-induced protein
aggregation and glycation decreases it chaperone
activity
The ability of whole fibrinogen to inhibit the thermal-induced
TTR aggregation was analyzed using plasma from healthy and
FAP subjects. After incubation at 43uC for 48 h, a substantially
larger amount of TTR precipitate was found in the plasma of
FAP individuals when compared to plasma of control individuals
(Figure 5A). Moreover not only the total amount of TTR is
higher, but also the amount of aggregated TTR (high molecular
mass protein bands) is also greater in FAP individuals. This
precipitation could be rescued by adding exogenous fibrinogen
(final concentration of 2.8 mg.mL
21) into the plasma of FAP
individuals before incubation (Figure 5B). However, the addition
of glycated fibrinogen to plasma does not rescue TTR
(Figure 5B). This result indicates that fibrinogen’s glycation by
methylglyoxal impairs its ability to inhibit TTR aggregation.
Considering the higher glycation levels of fibrinogen in FAP
patients, this might have an important impact in disease
progression.
To evaluate the effects of glycation on fibrinogen’s chaperone
activity, we incubated human fibrinogen with high purity
methylglyoxal, prepared in house as described, using 2.5 and
10 mM. Glycation by methylglyoxal was probed by Western blot,
showing as expected a dose-dependent glycation pattern
(Figure 5D). Since argpyrimidine modification of a-crystallin has
been described as largely responsible for its increased chaperone
function [49], this protein was also glycated in vitro and used as a
positive control. We then compared the ability of glycated and
non-glycated lens a-crystallin to prevent chemically induced
protein aggregation of two target proteins, insulin and lysozyme,
commonly used as model proteins for chaperone activity studies.
In agreement to previous reports, argpyrimidine modification
increased a-crystallin’s chaperone activity by nearly 2-fold,
reducing insulin aggregation (Figure 5E), Similar results were
obtained with lysozyme, confirming the increased chaperone
activity of a-crystallin upon glycation by methylglyoxal (Figure 5E).
As shown in Figure 5E, insulin and lysozyme aggregation were
significantly suppressed by fibrinogen (t-test for the significance of
the difference between the means of two independent samples;
p=0.011 for insulin and p=0.061 for lysozyme. Student’s-t test
with a 90% confidence interval. P#0.1 was considered statistically
significant). However, glycation by methylglyoxal significantly
reduces fibrinogen chaperone activity when both insulin and
lysozyme were used as target proteins, there is no statistical
significant diference between aggregation of insulin and lysozyme
alone (control) and in the presence of Glycated fibrinogen
(Fibrinogen+MG).
Figure 3. Time course analysis by Western blot of TTR and argpyrimidine modified proteins after liver transplantation. (A) Western
blot analysis of TTR in the plasma from DLT individuals over time (from 2 months to 4 years) and from OLT individuals over time (from 1 month to 11
years); (B) Western blot analysis of argpyrimidine modified proteins in the plasma from DLT individuals over time and from OLT individuals over time.
doi:10.1371/journal.pone.0024850.g003
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sion in FAP patients, as shown in Figure 5C. Higher levels of this
protein were also observed in other amyloid disorders, such as
Alzheimer and vascular dementia [51].
Discussion
In this work, we discovered that human plasma proteins are
differentially glycated in FAP patients in comparison with healthy
control subjects. Moreover, after DLT these glycated proteins
increase its abundance over time. We have also discovered that
fibrinogen, one of the differentially glycated proteins, is a TTR
interacting partner in plasma. Furthermore, it was recently
discovered that fibrinogen has chaperone activity and we
demonstrated in this work that upon glycation by methylglyoxal
its chaperone activity decreases. Taken together, these observa-
tions lead us to propose that fibrinogen glycation in vivo reduces its
chaperone activity, compromising TTR tetramer stability and
contributing to disease.
Although all FAP patients have identical concentrations of TTR
V30M in plasma and cerebrospinal fluid, age at onset varies
widely between 20 and 70 years. Therefore, despite the
identification of more than 80 TTR point mutations associated
with FAP, the process of fibril formation and its relationship with
pathogenesis remains unclear. Formation of amyloid fibrils by
non-mutated native TTR, as in senile systemic amyloidosis (SSA)
[7] implies that other factors besides genetic determinants must be
considered in FAP’s pathogenesis. Since the first symptoms in FAP
appear much earlier than in SSA, TTR point mutations only seem
to accelerate fibril formation by increasing the intrinsic TTR
amyloidogenicity.
The identification of glycation adducts in FAP patients was
previously described in long lived avascular tissues with low
turnover, like vitreous bodies and amyloid fibrils, being suggested
that these tissues were more prone to undergo glycation [52]. In
this work, we evaluated the presence of MAGE-modified proteins
in the plasma of FAP patients, relatively to healthy control
individuals. We identified two proteins differentially glycated by
argpyrimidine in FAP individuals. These results are surprising
since protein glycation is commonly associated to hyperglycaemia
conditions and FAP patients do not present a disturbed
metabolism of glucose, actually showing hypoglycaemia after
transient hyperinsulinemia upon oral administration of a loading
dose of glucose [53]. Furthermore, FAP patients show transient
Figure 4. TTR Protein binding assay in human plasma. (A) - TTR
was expressed in bacteria as GST fusion protein. After purification GST
alone and GST in fusion with TTR (GST-TTR) were incubated with
plasma, affinity purified with gluthathione beads and analysed by SDS-
PAGE. Purified fusion protein without plasma incubation (GST-TTR), GST
alone incubated with plasma (GST+Control Plasma for incubation with
plasma from control individuals and GST+FAP Plasma for incubation
with plasma from FAP individuals) were also analysed as controls.
Assigned protein bands were excised for identification (Table 2). (B)
Western blot analysis of fibrinogen after the pull down assay.
doi:10.1371/journal.pone.0024850.g004
Table 2. Identification of TTR interacting protein partners in human plasma.
Band Identification Accession code
Protein
Score
Protein
Score C. I. %
Total Ion
Score
Total Ion
C. I. %
Peptides
Matched
1 Fibrinogen beta chain FIBB_HUMAN 1250 100 1003 100 24
2 Fibrinogen beta chain FIBB_HUMAN 102 100 85 100 6
3 Fibrinogen gamma chain FIBG_HUMAN 1050 100 864 100 23
4 Fibrinogen alpha chain FIBA_HUMAN 1280 100 1227 100 25
5 Immunoglobulin mu-chain D-J4-region IGHM_HUMAN 630 100 542 100 20
6 Ig heavy chain V region M603 HVM20 157 100 150 100 8
7 Peptidyl-prolyl cis-trans isomerase Q13427 436 100 377 100 14
8 Retinol binding protein RET4 675 100 595 100 19
9 Serum albumin ALB 130 100 39 85 17
Protein band numbers are the ones assigned in Figure 4.
doi:10.1371/journal.pone.0024850.t002
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e24850Figure 5. Fibrinogen prevents plasma TTR thermal-induced protein aggregation and glycation decreases it chaperone activity. (A)
Western blot analysis of TTR in the plasma from three control and three FAP individuals after aggregation induced by temperature. (B) Western blot
analysis of TTR in the plasma from three FAP individuals after aggregation induced by temperature in the absence of fibrinogen, in the presence of
glycated fibrinogen and in the presence of non-glycated fibrinogen. (C) Western blot analysis of fibrinogen in the plasma from three control and
three FAP individuals, Western blot of sRAGE was used as loading control. (D) Coomassie blue stained gel of a-crystallin and fibrinogen without
glycation and glycated with 2.5 and 10 mM of methylglyoxal. Western blot analysis of argpyrimidine modified proteins. (E) Chemically (DTT) induced
protein aggregation of insulin and lysozyme (The aggregation of insulin and lysozyme alone, respectively, are used as controls) in the presence of a-
crystallin and fibrinogen with and without glycation. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0024850.g005
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differences were detected in sRAGE levels between control and
FAP subjects. Protein glycation is often associated with crosslink
formation, matrix dysfunction, reduced protein solubility and
increased protease resistance, implicated in the pathophysiology of
normal ageing and in the pathogenesis of the long-term clinical
complications of diabetes [54,55,56]. The formation of glycation
adducts depends on the plasma concentration of glucose,
methylglyoxal and other glycation agents [56] and these
compounds are strongly associated with the severity of diabetes
complications, particularly cardiovascular and renal ones. We
propose that the increased levels of methylglyoxal glycation found
in FAP might be related to renal failure. Indeed, in renal failure,
plasma and tissue levels of glycation adduct are completely
independent of plasma glucose [55]. FAP patients present low
levels of erythropoietin (EpoI), suggesting that these abnormalities
could be related to the amyloid deposits in renal interstitium [57].
Renal disease in FAP patients ranges from proteinuria to end-stage
renal failure, with replacement of renal function by dialysis. In
comparison to FAP patients with normal renal function, the
progression of the neurologic disease is delayed in FAP patients
enduring dialysis [58]. However, hemodialysis and hemodiafiltra-
tion are ineffective in removing TTR, in spite of the lower stability
of the TTR V30M variant. Since the protective feature of
hemodialysis on the progression of amyloidosis is not due to the
clearance of this abnormal protein from plasma [58], we suggest
that plasma glycation agents are removed by hemodialysis and so
their contribution to FAP decreases after this procedure. It might
be interesting to consider other glycation agents as well,
particularly fructose, more reactive than glucose and whose
plasma concentration is also dependent on dietary habits.
Different dietary habits have an impact on glycation and may
also contribute to explain individual differences [59].
Human fibrinogen specifically interacts with and suppresses
aggregation of a wide spectrum of stressed proteins [50]. It was
previously observed that human fibrinogen can inhibit the
formation of Sup35 fibril, which shares key features of amyloid
fibrils of mammalian prions and amyloid proteins [60] indicating a
Figure 6. Molecular model of the effects of fibrinogen glycation in vivo in FAP. In vitro studies established that amyloidogenic TTR variants
(as V30M) have a higher tendency to follow an aggregation pathway high the formation of amyloid deposits. Considering our findings that fibrinogen
interacts with TTR in the plasma, we proposed that fibrinogen chaperone activity reduces TTR propensity towards fibril formation. However, the
specific glycation of fibrinogen compromises its vital chaperone activity and in these conditions TTR becomes more prone to aggregation.
doi:10.1371/journal.pone.0024850.g006
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chaperone. It was suggested that fibrinogen may interact with
prefibrillar species during the fibril formation, redirecting the
aggregation process. It is also noteworthy that high levels of
fibrinogen are found in both Alzheimer’s disease and vascular
dementia [51]. In this work, we observed that fibrinogen
expression is increased in FAP patients. It is highly likely that
increased levels of fibrinogen in patients with different pathologies
that share common molecular mechanisms may be a response to
the increased need of extracellular chaperone activity under such
pathological conditions and they are aggravated by fibrinogen
glycation which decreases its chaperone activity, as discovered in
this work.
It is well known that protein structure and biological function
are altered upon glycation [56]. Considering our finding that
fibrinogen interacts with TTR in the plasma, we propose a new
molecular model for TTR aggregation that the fibrinogen
chaperone activity reduces TTR propensity towards fibril
formation. When fibrinogen is glycated, this function is compro-
mised and TTR becomes more prone to aggregation (Figure 6). A
molecular explanation on why plasma fibrinogen is more prone to
modification by methylglyoxal is not yet possible. Nevertheless,
studies with yeast cells show that among all its expressed proteins,
enolase (eno2p) is the most relevant glycation target [37]. Besides
eno2p being an abundant protein, arginine glycation sites were
identified in arginine rich clusters that might favor glycation by
methylglyoxal. The structure of fibrinogen was recently made
available and several potential arginine rich regions are apparent
[61]. Nevertheless, this is a matter for further research.
Although liver transplantation has become a well-established
treatment for halting the progression of FAP-related clinical
symptoms, no truly effective therapy has been designed [62,63,64]
and several problems have arisen from this procedure [65,66].
Timing for liver transplantation in still one of the main problems
associated to this therapy. First, FAP gene carriers who have no
clinical symptoms cannot undergo liver transplantation before the
onset of the disease. Second, FAP’s clinical complications present
before the surgery will remain unchanged after liver transplanta-
tion. Protein glycation in FAP may thus be an important
biomarker long before symptoms appear.
Finally, the effects of glycation on chaperone activity in
connection with conformational diseases are likely to be of high
relevance for the understanding of the biochemical mechanisms
underlying these pathologies and may offer pathways towards the
discovery of novel and effective therapeutic opportunities on
conformational diseases.
Supporting Information
Figure S1 Peptide mass Fingerprint of the TTR protein
band after tryptic digest in transplanted individuals
over time. A – The ion 1398,7 is present only in individuals that
carry the TTR V30M, and so FAP individuals and transplanted
with sequential liver and. This ion corresponds to the peptide with
the sequence GSPAINVAMHVFR of the TTR V30M. B - The
ion 1366.8 is present both in control and FAP individuals and also
in individuals transplanted with cavaderic liver and sequential
liver. This ion corresponds to the peptide with the sequence
GSPAINVAVHVFR of the TTR WT.
(TIF)
Table S1 Relative quantification of TTR in serum from
Sequential transplanted individuals and orthotic trans-
planted individuals, using peak 1394.732 as internal
standard (each value corresponds to the average of three
spectra acquired).
(DOC)
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